Technical Analysis for XENE - Xenon Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade C 9.4 1.84% 0.17
XENE closed up 1.84 percent on Friday, September 20, 2019, on 2.23 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Flat Up
See historical XENE trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
20 DMA Resistance Bearish 1.84%
Narrow Range Bar Range Contraction 1.84%
NR7 Range Contraction 1.84%
NR7-2 Range Contraction 1.84%
20 DMA Resistance Bearish 1.84%
MACD Bearish Signal Line Cross Bearish 1.84%
Fell Below 20 DMA Bearish 1.51%

Older signals for XENE ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is engaged in discovering and developing therapeutics for orphan indications. The company offers Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Its product candidates in development comprise TV-45070, which is in Phase IIb clinical trials for the treatment of osteoarthritis of the knee; and in Phase II proof-of-concept clinical trials for the treatment of postherpetic neuralgia and Erythromelalgia. It is also developing TV-45070 for neuropathic pain indications; and GDC-0276 for the treatment of pain. The company's preclinical product candidates include a sodium channel inhibitor to treat DRAVET SYNDROME, an orphan disorder; XEN801, a stearoyl Co-A desaturase, an inhibitor for the treatment of acne; and small-molecule inhibitors for the treatment of cardiovascular disease. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd., Genentech, Inc., and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Chemistry Biopharmaceutical Pain Chemical Compounds Organic Compounds Gene Therapy Osteoarthritis Acne Cardiovascular Disease Analgesics Genentech Treatment Of Osteoarthritis Indoles Lipoprotein Lipase Deficiency Alipogene Tiparvovec Glybera Postherpetic Neuralgia
Is XENE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.7
52 Week Low 5.41
Average Volume 41,218
200-Day Moving Average 8.9378
50-Day Moving Average 9.3992
20-Day Moving Average 9.346
10-Day Moving Average 9.344
Average True Range 0.3614
ADX 16.15
+DI 23.4109
-DI 14.0612
Chandelier Exit (Long, 3 ATRs ) 8.865799999999999
Chandelier Exit (Short, 3 ATRs ) 9.864199999999999
Upper Bollinger Band 9.8583
Lower Bollinger Band 8.8337
Percent B (%b) 0.55
BandWidth 10.962979
MACD Line 0.0075
MACD Signal Line 0.0142
MACD Histogram -0.0067
Fundamentals Value
Market Cap 169.17 Million
Num Shares 18 Million
EPS -1.66
Price-to-Earnings (P/E) Ratio -5.66
Price-to-Sales 65.85
Price-to-Book 1.07
PEG Ratio -0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.94
Resistance 3 (R3) 9.95 9.77 9.85
Resistance 2 (R2) 9.77 9.64 9.77 9.82
Resistance 1 (R1) 9.59 9.55 9.68 9.58 9.79
Pivot Point 9.41 9.41 9.46 9.41 9.41
Support 1 (S1) 9.23 9.28 9.32 9.22 9.01
Support 2 (S2) 9.05 9.19 9.05 8.98
Support 3 (S3) 8.87 9.05 8.95
Support 4 (S4) 8.86